Review of Combination Therapies for Neovascular Age-Related Macular Degeneration

REFERENCES

• Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study Monograph. Survey Ophthalmol 1980;24:335–610
   PubMedGoogle Scholar
• Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1992; 99:933–945.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K., Morita I., Tombran-Tink J., et al. Novel mechanism for age-related macular degener-ation: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189:323–333.
   PubMed Web of Science ®Google Scholar
• Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina 2009;29:S5–S7.
   Web of Science ®Google Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117(10):1329–1345.
   PubMedGoogle Scholar
• Michels S, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):371–376.
   PubMedGoogle Scholar
• Azab M et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123(4):448–457.
   PubMedGoogle Scholar
• Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001;119:399–404.
   PubMed Web of Science ®Google Scholar
• Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of pre-retinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103:2099–2104.
   PubMed Web of Science ®Google Scholar
• Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810–816.
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993;231:34–40.
   PubMed Web of Science ®Google Scholar
• Argenti D, Jensen BK, Hensel R, et al. A balance study to evaluate the biotransformation and excretion of [14C] triamcinolone acetonide following oral administration. J Clin Pharmacol. 2000;40:770–780.
   PubMed Web of Science ®Google Scholar
• Duguid IG, Boyd AW, Mandel TE. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res. 2000;11(Suppl):153–159.
   Google Scholar
• Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability andexpression of vascular endothelial growth factor. Eur J Pharmacol. 2001;411(3):231–243.
   PubMedGoogle Scholar
• Sommer A, Veraart J, Neumann M, et al. Evaluation of vasoconstrictive effects of topical steroids by lasesr-Doppler-perfusion-imaging. Acta Derm Venereol. 1998;78:15–18.
   PubMed Web of Science ®Google Scholar
• Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol. 2001;425:109–116.
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686.
   PubMed Web of Science ®Google Scholar
• Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740–743.
   PubMed Web of Science ®Google Scholar
• Galor A, Margolis R, Brasil OMF, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmololgy. 2007;114:1912–1918.
   PubMed Web of Science ®Google Scholar
• Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23(5):686–691.
   PubMedGoogle Scholar
• Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol. 2006;141(3):579–580.
   PubMedGoogle Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259–266.
   PubMed Web of Science ®Google Scholar
• Wu WS, Wang FS, Yang KD, Huang CC, Kuo YR. Dexamethasone induction of keloid regression th rough effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006;126:1264–1271.
   PubMed Web of Science ®Google Scholar
• Busch T. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment. Retina 2009;29:S36–S38.
   PubMed Web of Science ®Google Scholar
• Papadopoulou DN, Mendrinos E, Magioris G, Donait G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1755–1761.
   PubMedGoogle Scholar
• Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1731–1739.
   PubMedGoogle Scholar
• Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, Pruente C, and Schmidt-Erfurth U. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: Long-term results. Eye 2009;23(12): 2223–2227.
   PubMedGoogle Scholar
• Roth DB, Kulkarni KM, Walsman S, and Modi A. Intravitreal triamcinolone acetonide preceding photodynamic therapy for exudative age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 2009;40(5): 467–471.
   PubMedGoogle Scholar
• Maberley D and Canadian retinal trials group. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 2009;116(11: 2149–57.
   PubMedGoogle Scholar
• Frimpong-Boateng A, Bunse A, Rufer F, and Roider J. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: Functional results in 54 patients. Acta Ophthalmologica 2009;87(2): 183–187.
   PubMedGoogle Scholar
• Sacu S, Varga A, Michels S, Weigert G, Polak K, Vecsei-Marlovits PV, and Schmidt-Erfurth U. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: Short-term results of a randomised study. British Journal of Ophthalmology 2008;92(10): 1347–1351.
   PubMedGoogle Scholar
• Rouvas AA, Papakostas TD, Ladas ID, and Vergados I. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. Graefes Archive for Clinical & Experimental Ophthalmology 2008;246(2): 315–318.
   PubMedGoogle Scholar
• Piermarocchi S, Sartore M, Lo Giudice G, Maritan V, Midena E, and Segato T. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. Archives of Ophthalmology 2008;126(10): 1367–1374.
   PubMedGoogle Scholar
• Iwama D, Otani A, Sasahara M, Yodoi Y, Gotoh N, Tamura H, Tsujikawa A, and Yoshimura N. Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. British Journal of Ophthalmology 2008;92(10): 1352–1356.
   PubMedGoogle Scholar
• Blaha GR, Wertz IFD, and Marx JL. Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide. Ophthalmic Surgery Lasers and Imaging 2008;39(1): 6–11.
   PubMedGoogle Scholar
• Schadlu R, Kymes SM, and Apte RS. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: Effect of initial visual acuity on treatment response. Graefes Archive for Clinical & Experimental Ophthalmology 2007;245(11): 1667–1672.
   PubMedGoogle Scholar
• Ruiz-Moreno JM, Montero JA and Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 2007;27(4): 458–461.
   PubMedGoogle Scholar
• Ruiz-Moreno JM, Montero JA, Barile S and Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006;26(6): 602–612.
   PubMedGoogle Scholar
• Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, and Wilson DJ. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 2007;114(9): 1713–1721.
   PubMedGoogle Scholar
• Chaudhary V, Mao A, Hooper PL, and Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: A prospective randomized trial. Ophthalmology 2007;114(12): 2183–2189.
   PubMedGoogle Scholar
• Shah C. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration: A comparative study - Commentary. Evidence-Based Ophthalmology 2006;7(3): 132–134.
   Google Scholar
• Ruiz-Moreno JM, Montero JA, and Barile S. Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. European Journal of Ophthalmology 2006;16(3): 426–434.
   PubMedGoogle Scholar
• Mantel I, Ambresin A, and Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. European Journal of Ophthalmology 2006;16(5): 705–710.
   PubMedGoogle Scholar
• Krebs I, Binder S, and Stolba U. A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefes Archive for Clinical & Experimental Ophthalmology 2006;244(7): 863–7.
   PubMedGoogle Scholar
• Fackler TK, Reddy S, Bearelly S, Stinnett S, Fekrat S, and Cooney MJ. Retrospective review of eyes with neovascular age-related macular degeneration treated with photodynamic therapy with verteporfin and intravitreal triamcinolone. Annals of the Academy of Medicine, Singapore 2006;35(10): 701–705.
   PubMedGoogle Scholar
• Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, and Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: A comparative study. British Journal of Ophthalmology 2006;90(3): 337–341.
   PubMedGoogle Scholar
• Ergun E, Maar N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, and Stur M. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. American Journal of Ophthalmology 2006;142(1): 10–16.
   PubMedGoogle Scholar
• Augustin AJ, and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration[see comment]. Ophthalmology 2006;113(1): 14–22.
   PubMedGoogle Scholar
• Augustin AJ, and Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology 2006;141(4): 638–645.
   PubMedGoogle Scholar
• Aggio FB, Melo GB, Hofling-Lima AL, and Eid Farah M. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica Scandinavica 2006;84(6): 831–833.
   PubMedGoogle Scholar
• Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356–360.
   PubMed Web of Science ®Google Scholar
• Arias L, Garcia Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: One-year results of a randomized study. Ophthalmology. 2006; 113(12):2243–2250.
   PubMedGoogle Scholar
• Singh CN, Saperstein DA. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008;28:789–793.
   PubMed Web of Science ®Google Scholar
• Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: Short-term results of a randomised study. Br J Ophthalmol. 2008;92:1347–1351.
   PubMedGoogle Scholar
• Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142:95–104.
   PubMed Web of Science ®Google Scholar
• Calvo-Gonzalez C, Reche-Frutos J, Donate-Lopez J, Garcia-Feijoo J, Leila M, Fernandez-Perez C, and Garcia-Sanchez J. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration. British Journal of Ophthalmology 2008;92(1): 74–5.
   PubMedGoogle Scholar
• Dhalla MS, Shah GK, Blinder KJ, Ryan Jr EH, Mittra RA and Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26(9): 988–993.
   PubMedGoogle Scholar
• Kaiser PK, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T and Strong HA. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116(4): 747–755.
   PubMedGoogle Scholar
• Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan Jr EH, and Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008;28(5): 675–681.
   PubMedGoogle Scholar
• Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, and Vergados I. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 2007;27(7): 891–896.
   PubMedGoogle Scholar
• Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M and Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. European Journal of Ophthalmology 2008;18(2): 297–300.
   PubMedGoogle Scholar
• Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG and Eter N. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Archive for Clinical & Experimental Ophthalmology 2008;246(1): 17–25.
   PubMedGoogle Scholar
• Navea A, Mataix J, Desco MC, Garcia-Pous M and Palacios E. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration. Retina 2009;29(1): 13–19.
   PubMedGoogle Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114(6):1179–1185.
   PubMedGoogle Scholar
• Rouvas AA, Papakostas TD, Ladas ID, and Vergados I. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. Graefes Archive for Clinical & Experimental Ophthalmology 2008;246(2): 315–318.
   PubMedGoogle Scholar
• Kumar A, Gopalakrishnan K and Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: A pilot study. Retina 2008;28(9): 1296–1301.
   PubMedGoogle Scholar
• Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of FOCUS study. Arch Ophthalmol. 2006;124:1532–1543.
   PubMed Web of Science ®Google Scholar
• Antosyzk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am J Ophthalmol. 2008;145(5):862–874.
   PubMedGoogle Scholar
• Kim IK, Husain D, Michaud N, et al. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006;47:357–363.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934.
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133–140.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009;29:573–578.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmology 2007;7:10.
   PubMedGoogle Scholar